» Articles » PMID: 25136121

Immune Evasion Mediated by Tumor-derived Lactate Dehydrogenase Induction of NKG2D Ligands on Myeloid Cells in Glioblastoma Patients

Overview
Specialty Science
Date 2014 Aug 20
PMID 25136121
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

Myeloid cells are key regulators of the tumor microenvironment, governing local immune responses. Here we report that tumor-infiltrating myeloid cells and circulating monocytes in patients with glioblastoma multiforme (GBM) express ligands for activating the Natural killer group 2, member D (NKG2D) receptor, which cause down-regulation of NKG2D on natural killer (NK) cells. Tumor-infiltrating NK cells isolated from GBM patients fail to lyse NKG2D ligand-expressing tumor cells. We demonstrate that lactate dehydrogenase (LDH) isoform 5 secreted by glioblastoma cells induces NKG2D ligands on monocytes isolated from healthy individuals. Furthermore, sera from GBM patients contain elevated amounts of LDH, which correlate with expression of NKG2D ligands on their autologous circulating monocytes. NKG2D ligands also are present on circulating monocytes isolated from patients with breast, prostate, and hepatitis C virus-induced hepatocellular carcinomas. Together, these findings reveal a previously unidentified immune evasion strategy whereby tumors produce soluble factors that induce NKG2D ligands on myeloid cells, subverting antitumor immune responses.

Citing Articles

Immune Cell Interplay in the Fight Against GBM.

Vallieri N, Datsi A Cancers (Basel). 2025; 17(5).

PMID: 40075663 PMC: 11899300. DOI: 10.3390/cancers17050817.


Metabolic adaptation of myeloid cells in the glioblastoma microenvironment.

Essakhi N, Bertucci A, Baeza-Kallee N, Colin C, Lavignolle-Heguy R, Garcia-Gonzalez P Front Immunol. 2025; 15:1431112.

PMID: 39763643 PMC: 11700814. DOI: 10.3389/fimmu.2024.1431112.


CAR-T cell therapy for the treatment of adult high-grade gliomas.

Park S, Maus M, Choi B NPJ Precis Oncol. 2024; 8(1):279.

PMID: 39702579 PMC: 11659528. DOI: 10.1038/s41698-024-00753-0.


Natural killer cells in cancer immunotherapy.

Wang D, Dou L, Sui L, Xue Y, Xu S MedComm (2020). 2024; 5(7):e626.

PMID: 38882209 PMC: 11179524. DOI: 10.1002/mco2.626.


Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.

Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y J Hematol Oncol. 2024; 17(1):31.

PMID: 38720342 PMC: 11077829. DOI: 10.1186/s13045-024-01544-7.


References
1.
Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A . TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain. 2006; 129(Pt 9):2416-25. DOI: 10.1093/brain/awl205. View

2.
Groh V, Wu J, Yee C, Spies T . Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002; 419(6908):734-8. DOI: 10.1038/nature01112. View

3.
Champsaur M, Lanier L . Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 2010; 235(1):267-85. PMC: 2885032. DOI: 10.1111/j.0105-2896.2010.00893.x. View

4.
Orr M, Lanier L . Natural killer cell education and tolerance. Cell. 2010; 142(6):847-56. PMC: 2945212. DOI: 10.1016/j.cell.2010.08.031. View

5.
Ogasawara K, Hamerman J, Hsin H, Chikuma S, Bour-Jordan H, Chen T . Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity. 2003; 18(1):41-51. DOI: 10.1016/s1074-7613(02)00505-8. View